Grandbrothers/iStock Editorial via Getty Images
Summit Therapeutics (NASDAQ:SMMT) shares rose as much as 25% in premarket trading on Friday after the company secured FDA’s Fast Track designation for the proposed use of its cancer drug, ivonescimab, in combination with platinum-based chemotherapy for the treatment of
